GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (FRA:HHU) » Definitions » Quick Ratio

Allergy Therapeutics (FRA:HHU) Quick Ratio : 1.01 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Allergy Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Allergy Therapeutics's quick ratio for the quarter that ended in Jun. 2024 was 1.01.

Allergy Therapeutics has a quick ratio of 1.01. It generally indicates good short-term financial strength.

The historical rank and industry rank for Allergy Therapeutics's Quick Ratio or its related term are showing as below:

FRA:HHU' s Quick Ratio Range Over the Past 10 Years
Min: 1.01   Med: 2.18   Max: 3.64
Current: 1.01

During the past 13 years, Allergy Therapeutics's highest Quick Ratio was 3.64. The lowest was 1.01. And the median was 2.18.

FRA:HHU's Quick Ratio is ranked worse than
62.64% of 1036 companies
in the Drug Manufacturers industry
Industry Median: 1.395 vs FRA:HHU: 1.01

Allergy Therapeutics Quick Ratio Historical Data

The historical data trend for Allergy Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Quick Ratio Chart

Allergy Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.47 2.58 1.72 1.18 1.01

Allergy Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 1.58 1.18 0.93 1.01

Competitive Comparison of Allergy Therapeutics's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allergy Therapeutics's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Quick Ratio falls into.



Allergy Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Allergy Therapeutics's Quick Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Quick Ratio (A: Jun. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(39.574-15.063)/24.283
=1.01

Allergy Therapeutics's Quick Ratio for the quarter that ended in Jun. 2024 is calculated as

Quick Ratio (Q: Jun. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(39.574-15.063)/24.283
=1.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (FRA:HHU) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Allergy Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany, Austria, Netherlands, and Switzerland.

Allergy Therapeutics Headlines

No Headlines